Dupilumab reduces risk of severe exacerbations and improves FEV1 in patients on both high- and medium dose ICS with uncontrolled, moderate-to-severe asthma from the phase 3 LIBERTY ASTHMA QUEST Study

Dupilumab reduces risk of severe exacerbations and improves FEV1 in patients on both high- and medium dose ICS with uncontrolled, moderate-to-severe asthma from the phase 3 LIBERTY ASTHMA QUEST Study

Bibliographische Detailangaben
Hauptverfasser: Pavord, I, Papi, A, Wenzel, S, Park, H, Zhang, B, Staudinger, H, Maroni, J, Rowe, P, Amin, N, Pirozzi, G, Ruddy, M, Akinlade, B, Graham, N, Teper, A
Format: Conference item
Veröffentlicht: Wiley 2018

Ähnliche Einträge